Therefore, it is possible that any EGFR-TK-directed therapy should consider anticancer targets in the tumour stroma as well as neoplastic epithelium, and, indeed, perhaps such TK-directed therapy in breast cancer will predominantly affect this tumour–microenvironment interaction by inhibiting invasion and progression rather than influence tumour mass. The gene discussed is TKT; the disease is breast carcinoma.